Core Insights - NeuroSense Therapeutics Ltd. has scaled up the production of its lead drug candidate, PrimeC, to a commercial scale, which is an extended-release oral formulation combining ciprofloxacin and celecoxib for treating amyotrophic lateral sclerosis (ALS) [1][2] - The company has enhanced its supply chain through comprehensive Chemistry, Manufacturing, and Controls (CMC) improvements and has partnered with a global contract development and manufacturing organization (CDMO) for future commercial supply [2][3] - Stability data indicates a shelf life of at least 36 months at room temperature, and the formulation's intellectual property protection extends until 2042 [3] Commercial Potential - Forecasts suggest that PrimeC could achieve peak annual revenues of $100–150 million in Canada [4] - D. Boral Capital has initiated coverage on NeuroSense with a Buy rating and a price target of $14, citing strong mechanistic rationale supported by preclinical and translational research [4] - The ongoing Phase 2b PARADIGM trial is expected to provide further validation, with topline results anticipated in the second half of 2025 [4] Clinical Developments - Recent findings from the Phase 2b PARADIGM clinical trial indicate that PrimeC significantly impacts microRNA modulation, which is crucial for understanding its potential to slow ALS progression [5][6] - The treatment has shown a 33% reduction in disease progression and a 58% improvement in survival rates [6] Expansion and Strategic Partnerships - NeuroSense is exploring expansion into Alzheimer's and Parkinson's diseases, utilizing similar pathophysiologic targets with modified drug combinations, which could broaden its market reach [7] - The company is in advanced discussions with several multi-billion-dollar pharmaceutical companies for a potential strategic partnership to develop and commercialize PrimeC for ALS [8] - The stock price of NeuroSense has increased by 6.34%, reaching $1.11 [8]
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights